Bright future: A new vision for eye health

By Mark Steedman, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-bright-future-eye

This week’s blog is the third in our series focusing on eye health, which we developed in support of a global policy report that was launched this week at the World Innovation Summit for Health (WISH). Our first blog in the series focused on glaucoma, while our second examined new treatments for age-related macular degeneration (AMD). This latest blog focuses on the main findings and recommendations of the full report Bright future: A new vision for eye health.

Continue reading

Posted on 16/11/2018 | 0 Comments

A bold future for life sciences regulation: Predictions 2025

By Karen Taylor, Director, Centre for Health Solutions

Deloitte-uk-life-sciences-predictions-2025-banner

Following our 2014 and 2017 Life Science and Health Care Predictions reports, ‘A bold future?’ and ‘The future awakens’, this week we launched our third predictions report, A bold future for Life Sciences Regulation: Predictions 2025. This year’s report presents an unashamedly optimistic view on what Life Sciences regulation might look like in 2025 if both life science companies and regulators were to work more collaboratively, embrace disruptive technologies, and acquire new skills and talent. We argue that this would improve not only the productivity of the regulators and industry but also provide patients with access to the latest medical innovation much sooner. We also imagine through a series of ‘portraits’ how a regulator, company and patient might behave in 2025. This week’s blog provides an overview of the four predictions presented in our future of regulation report and examples of the evidence today that enable us to predict a bold future for life sciences regulation in 2025.

Continue reading

Posted on 08/11/2018 | 0 Comments

The rise of e-mental health: How can digital technology build resilience?

By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-the-rise-of-e-mental-health

Earlier this year, a team of US scientists connected the brains of three people using an interface made of electroencephalography and magnetic stimulation technologies. The new network enabled the three people to communicate by thinking, exchange ideas and successfully play a collaborative game.1 This ground-breaking experiment is yet one example of many other recent scientific advances where digital technologies are transforming our understanding of the mind. While controversial and somewhat alarming, these developments also present a unique opportunity to protect and support mental health, at a time of unprecedented technological changes.

Continue reading

Posted on 02/11/2018 | 0 Comments

Digital transformation in biopharma: Time for a sea change in strategy

By Mark Steedman, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-boat-navigators-through-lens

Deloitte recently conducted a survey with the MIT Sloan Management Review to assess the digital maturity of companies across a wide variety of industries.1 Our colleagues in the US Center for Health Solutions analysed the responses from biopharma companies and published them in a separate report - Survey finds biopharma companies lag in digital transformation: It is time for a sea change in strategy.2 Headlining the report is the finding that only 20 per cent of biopharma respondents think their companies are digitally mature, compared to 30 per cent across all industries.3 

Continue reading

Posted on 26/10/2018 | 0 Comments

Insights from our State of the State 2018-19 report: How health sector leaders and citizens view the outlook for NHS and social care services

By Karen Taylor, Director, Centre for Health Solutions

Sots

Last week, my public sector colleagues, together with the think tank Reform, published their seventh annual report The State of the State 2018-19: Government beyond Brexit.1 The report once again brought together Deloitte and Reform to reflect on our most pressing public sector issues. The evidence for the report includes a deep analysis of published data, a citizen survey and exclusive interviews with the people who understand the public sector’s challenges best – the people who run it. As in previous years, the NHS and social care are a central feature of the report, and I have used this week’s blog to highlight the main findings on the ‘State of the NHS and social care’.

Continue reading

Posted on 19/10/2018 | 0 Comments

World Mental Health Day: ‘R U OK’?

By Elizabeth Hampson, Director, Monitor Deloitte

World-health-day

Wednesday 10th October was World Mental Health Day 2018, and coincidentally last week I presented the findings from our work in support of the independent review of mental health and employers by Lord Dennis Stevenson and Paul Farmer ‘Thriving at Work’.1 Our report Mental Health and Wellbeing in Employment: A supporting study for the Independent Review explored the cost of poor mental health and the return on investment for employers from mental health interventions in the workplace, and showcased good practice examples from other countries.2 My presentation, in conjunction with Mind, the mental health charity whose CEO is Paul Farmer, was to senior executives from all Virgin companies at one of the Branson homes in Oxfordshire.

Continue reading

Posted on 11/10/2018 | 0 Comments

Fighting the opioid crisis – a UK perspective

By Matthew Thaxter

Tablets

By now, it is likely that most people have heard about the ongoing opioid crisis in the US, as barely a day goes by without some form of media coverage. Recent stories have also emerged of a significant upward trend in opioid prescriptions in the UK. This blog explores some of the drivers behind the US crisis, and how likely we are to see a similar epidemic here in the UK.

Continue reading

Posted on 05/10/2018 | 0 Comments

Consumers want connected medical devices, but demand for digital experts could put further strain on the talent pool for medtech

By Pedro Arboleda, managing director, Deloitte Consulting LLP

Medical

This week, running from September the 24th to the 26th, our colleagues in the US attended AdvaMed’s annual MedTech Conference. At the conference participants heard about the latest innovations, such as new digital products that incorporate the latest advances in wireless technology and increasingly powerful computing capabilities for generating clinical and economic insights. This week’s blog, by Pedro Arboleda, first appeared on the US Center for health solutions website.1 Below, he discusses his worry that given the rapid advancement in digital technologies the industry might overlook another important change that is occurring in parallel—the ability to attract the specific digital talent needed to deliver on the promise of connected medical devices.

Continue reading

Posted on 28/09/2018 | 0 Comments

World Alzheimer’s Day

By Mark Steedman, PhD. Manager Centre for Health Solutions

Alzhimer

In the late 1970s, Earth, Wind & Fire released one of their biggest hits – September – with an opening line that has become an internet meme and is widely recognised around the world.

“Do you remember the 21st night of September?”

Continue reading

Posted on 21/09/2018 | 0 Comments

Turbo charge your drug development: How pharma companies should use emerging technologies

by Dr Francesca Properzi PhD

Drug

 We are delighted to use this week’s blog to introduce the Centre’s new Research Manager, Francesca Properzi, who joined the team last week. Here is Francesca’s take on the way emerging technologies can improve pharma R&D.

R&D management in the pharmaceutical industry is facing unprecedented challenges. While the availability of new high-impact technologies has the potential to help reshape research and clinical development, our latest report from our Measuring the return from pharmaceutical innovation series, A new future for R&D?, shows the costs of drug development for 12 large cap pharma companies has increased sharply over the past eight years by nearly 50 per cent, totalling just under $2 billion per drug.  Although a number of therapies are still expected to achieve blockbuster status, lower projected R&D returns are decreasing sharply from a once double digit high to an average of slightly over three per cent. This exceedingly low internal rate of return (IRR), is mostly due to companies paying the price of lower post-approval sales and increased R&D costs.   

Continue reading

Posted on 14/09/2018 | 0 Comments

Eight IoT barriers for connected medical devices…and how to overcome them

by Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte Consulting LLP

Medtech

In July 2018, we released our report, Medtech and The Internet of Medical Things, which examined the proliferation of medical grade Internet of Things (IoT) technologies, the benefits they provide, the challenges that need to be overcome for them to become a staple in health care delivery and what the future of the medtech industry may look like. This week’s blog, by Deloitte’s global Life Sciences leader Greg Reh, first appeared on the US Center for Health Solutions blog site.1 The blog presents his take on some of the findings from the report, and the challenges and opportunities for Medtech in this rapidly evolving space.

Continue reading

Posted on 07/09/2018 | 0 Comments